Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.

Dahal LN, Huang CY, Stopforth RJ, Mead A, Chan K, Bowater JX, Taylor MC, Narang P, Chan HTC, Kim JH, Vaughan AT, Forconi F, Beers SA.

J Immunol. 2018 Aug 15;201(4):1211-1221. doi: 10.4049/jimmunol.1701122. Epub 2018 Jul 11.

PMID:
29997125
2.

Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics.

Dalziel M, Beers SA, Cragg MS, Crispin M.

Glycobiology. 2018 Sep 1;28(9):697-712. doi: 10.1093/glycob/cwy043.

PMID:
29800150
3.

The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells.

Banerjee A, Arvinrad P, Darley M, Laversin SA, Parker R, Rose-Zerilli MJJ, Townsend PA, Cutress RI, Beers SA, Houghton FD, Birts CN, Blaydes JP.

Oncotarget. 2018 May 1;9(33):23274-23288. doi: 10.18632/oncotarget.25299. eCollection 2018 May 1.

4.

UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.

Dahal LN, Gadd A, Edwards AD, Cragg MS, Beers SA.

Scand J Immunol. 2018 Jun;87(6):e12666. doi: 10.1111/sji.12666. Epub 2018 May 6.

PMID:
29667229
5.

Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.

Zeidan B, Manousopoulou A, Garay-Baquero DJ, White CH, Larkin SET, Potter KN, Roumeliotis TI, Papachristou EK, Copson E, Cutress RI, Beers SA, Eccles D, Townsend PA, Garbis SD.

Breast Cancer Res. 2018 Mar 22;20(1):19. doi: 10.1186/s13058-018-0938-6.

6.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH.

Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30.

7.

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH.

Cancer Res. 2017 Jun 15;77(12):3376-3378. doi: 10.1158/0008-5472.CAN-17-0412. Epub 2017 Jun 5. No abstract available.

8.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

9.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

10.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

11.

Influence of immunoglobulin isotype on therapeutic antibody function.

Beers SA, Glennie MJ, White AL.

Blood. 2016 Mar 3;127(9):1097-101. doi: 10.1182/blood-2015-09-625343. Epub 2016 Jan 13. Review.

12.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

13.

FcγR requirements leading to successful immunotherapy.

Dahal LN, Roghanian A, Beers SA, Cragg MS.

Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342. Review.

PMID:
26497516
14.

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.

Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA.

Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. No abstract available.

15.

Antibody modulation: Limiting the efficacy of therapeutic antibodies.

Vaughan AT, Cragg MS, Beers SA.

Pharmacol Res. 2015 Sep;99:269-75. doi: 10.1016/j.phrs.2015.07.003. Epub 2015 Jul 15.

PMID:
26188150
16.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

17.

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG, Cragg MS, Beers SA.

Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.

18.

Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Vaughan AT, Chan CH, Klein C, Glennie MJ, Beers SA, Cragg MS.

J Biol Chem. 2015 Feb 27;290(9):5424-37. doi: 10.1074/jbc.M114.593806. Epub 2015 Jan 7.

19.

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11.

20.

FcγRIIB as a key determinant of agonistic antibody efficacy.

White AL, Beers SA, Cragg MS.

Curr Top Microbiol Immunol. 2014;382:355-72. doi: 10.1007/978-3-319-07911-0_16. Review.

PMID:
25116108
21.

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA.

J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14.

22.

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, Shah V, Roghanian A, Frendéus B, Glennie MJ, Cragg MS.

Blood. 2014 Jan 30;123(5):669-77. doi: 10.1182/blood-2013-04-490821. Epub 2013 Nov 13.

23.

Neutrophils: "neu players" in antibody therapy?

Beers SA, Glennie MJ.

Blood. 2013 Oct 31;122(18):3093-4. doi: 10.1182/blood-2013-09-525451. No abstract available.

24.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

25.

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Review.

PMID:
23543215
26.

Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice.

MacLellan LM, Montgomery J, Sugiyama F, Kitson SM, Thümmler K, Silverman GJ, Beers SA, Nibbs RJ, McInnes IB, Goodyear CS.

Arthritis Rheum. 2011 Dec;63(12):3897-907. doi: 10.1002/art.30629.

27.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

28.

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.

29.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.

30.

CD20 as a target for therapeutic type I and II monoclonal antibodies.

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ.

Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Review.

PMID:
20350657
31.

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS.

Blood. 2010 Jun 24;115(25):5191-201. doi: 10.1182/blood-2010-01-263533. Epub 2010 Mar 11.

32.

Complement: help or hindrance?

Beers SA, Cragg MS, Glennie MJ.

Blood. 2009 Dec 24;114(27):5567-8; author reply 5568. doi: 10.1182/blood-2009-10-249466. No abstract available.

33.

Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors.

Unruh TL, Zuccolo J, Beers SA, Kanevets U, Shi Y, Deans JP.

J Immunother. 2010 Jan;33(1):30-9. doi: 10.1097/CJI.0b013e3181b290f1.

PMID:
19952958
34.

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS.

Haematologica. 2010 Jan;95(1):135-43. doi: 10.3324/haematol.2008.001628. Epub 2009 Sep 22. Review.

35.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS.

J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.

36.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ.

Blood. 2008 Nov 15;112(10):4170-7. doi: 10.1182/blood-2008-04-149161. Epub 2008 Jun 26.

37.

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, Glennie MJ, Cragg MS.

J Biol Chem. 2008 Jun 20;283(25):16971-84. doi: 10.1074/jbc.M708459200. Epub 2008 Apr 21.

38.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG.

J Immunol. 2006 Jul 1;177(1):362-71.

40.
41.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.

42.

Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45.

Beers SA, Malloy EA, Wu W, Wachter MP, Gunnia U, Cavender D, Harris C, Davis J, Brosius R, Pellegrino-Gensey JL, Siekierka J.

Bioorg Med Chem. 1997 Dec;5(12):2203-11.

PMID:
9459018
43.

Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.

Kirchner T, Argentieri DC, Barbone AG, Singer M, Steber M, Ansell J, Beers SA, Wachter MP, Wu W, Malloy E, Stewart A, Ritchie DM.

J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.

44.

N-(5-substituted) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase.

Beers SA, Malloy EA, Wu W, Wachter M, Ansell J, Singer M, Steber M, Barbone A, Kirchner T, Ritchie D, Argentieri D.

Bioorg Med Chem. 1997 Apr;5(4):779-86.

PMID:
9158876
45.

Phosphatase inhibitors--III. Benzylaminophosphonic acids as potent inhibitors of human prostatic acid phosphatase.

Beers SA, Schwender CF, Loughney DA, Malloy E, Demarest K, Jordan J.

Bioorg Med Chem. 1996 Oct;4(10):1693-701.

PMID:
8931939
46.

Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats.

Zimmerman CL, Remmel RP, Ibrahim SS, Beers SA, Vince R.

Drug Metab Dispos. 1992 Jan-Feb;20(1):47-51.

PMID:
1346995
47.

Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Lee KH, Beers SA, Mori M, Wang ZQ, Kuo YH, Li L, Liu SY, Chang JY, Han FS, Cheng YC.

J Med Chem. 1990 May;33(5):1364-8.

PMID:
2158562
48.

Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II.

Lee KH, Imakura Y, Haruna M, Beers SA, Thurston LS, Dai HJ, Chen CH, Liu SY, Cheng YC.

J Nat Prod. 1989 May-Jun;52(3):606-13.

PMID:
2550587
49.

Antitumor agents, 99. Synthetic ring C aromatized podophyllotoxin analogues as potential inhibitors of human DNA topoisomerase II.

Beers SA, Imakura Y, Dai HJ, Li DH, Cheng YC, Lee KH.

J Nat Prod. 1988 Sep-Oct;51(5):901-5.

PMID:
2849640

Supplemental Content

Loading ...
Support Center